Abstract
Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.
Keywords: Plk1, osteosarcoma, cancer, therapy, target.
Current Pharmaceutical Design
Title:Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Volume: 21 Issue: 10
Author(s): Li Cheng, Chongchong Wang and Juehua Jing
Affiliation:
Keywords: Plk1, osteosarcoma, cancer, therapy, target.
Abstract: Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.
Export Options
About this article
Cite this article as:
Cheng Li, Wang Chongchong and Jing Juehua, Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612820999141029162811
DOI https://dx.doi.org/10.2174/1381612820999141029162811 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies A Validated HPLC-PDA Method for the Analysis of Ursolic Acid Content in Poly(lactic acid) Nanoparticles
Current Chromatography Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Assessment of Gene Transfer Using Imaging Methodology
Current Genomics p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Editorial
Current Medical Imaging DNA Methylation, Chondrogenesis, and Cartilage Degeneration
Current Rheumatology Reviews Broadening Our View of Protective Antibody Responses Against HIV
Current HIV Research Effect-based Hazard Identification of House Dust by In Vitro Assays Detecting Dioxin-like Compounds, Thyroid and Reproductive Toxicants
Current Organic Chemistry Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Non-Viral Gene Delivery to the Lungs
Current Gene Therapy Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma
Current Cancer Drug Targets Notch-Associated MicroRNAs in Cancer
Current Drug Targets Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design